Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Pfizer stories

Nov 11, 2026

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Pfizer has struck a deal with Blackstone to receive up to $1.5 billion through 2028 to fund development of an experimental monthly obesity treatment, as the company races to compete in the GLP-1 market without a currently approved weight-loss drug.

Nov 11, 2026·3 sources
00
Nov 6, 2026

GSK and Moderna settle patent dispute over COVID and RSV vaccines

GSK has settled lawsuits accusing Moderna's COVID-19 vaccines Spikevax and mNEXSPIKE and RSV shot mResvia of infringing its patents, resolving a major intellectual property dispute between the two drugmakers.

Nov 6, 2026·2 sources
00
Nov 3, 2026

Pfizer raises 2026 outlook on strong demand for non-Covid drugs

Pfizer raised its full-year profit and revenue outlook after third-quarter results beat estimates, driven by growing demand for newly launched and acquired medicines as Covid product sales decline.

Nov 3, 2026·4 sources
00
Oct 26, 2026

FDA expands talazoparib approval for metastatic prostate cancer

The FDA approved the PARP inhibitor talazoparib in combination with enzalutamide for treatment of patients with metastatic androgen pathway modulation-naive or -sensitive prostate cancer.

Oct 26, 2026·2 sources
00
Oct 7, 2026

FDA approves Pfizer's TUKYSA as first-line maintenance treatment for HER2+ metastatic breast cancer

The FDA approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a chemotherapy-free maintenance treatment for adults with HER2-positive metastatic breast cancer. The approval was supported by data showing more than 50% improvement in median progression-free survival.

Oct 7, 2026·4 sources
00
Oct 5, 2026

Vaxcyte pneumococcal vaccine succeeds in Phase 3 trial

Vaxcyte's experimental pneumococcal vaccine generated immune responses comparable to Pfizer and Merck vaccines in a Phase 3 trial, positioning it to compete in the lucrative vaccine market.

Oct 5, 2026·3 sources
00
Oct 1, 2026

Florida attorney general sues Pfizer over COVID-19 vaccine claims

Florida Attorney General James Uthmeier filed a lawsuit against Pfizer and CEO Albert Bourla, accusing the drugmaker of misleading consumers about the safety and effectiveness of its COVID-19 vaccine.

Oct 1, 2026·2 sources
00

HRSA approves 10 drugmakers for revised 340B rebate pilot program covering 21 drugs

The Trump administration released a list of 10 pharmaceutical companies, including AbbVie, Merck, and Pfizer, that will be allowed to shift from upfront discounts to after-the-fact rebates on 21 drugs in the 340B drug discount program starting January 1. The revised pilot program includes more manufacturers than the administration's first attempt at a rebate program.

Oct 1, 2026·3 sources
00

Pfizer's tilrekimig meets primary goal in phase 2 eczema trial

Pfizer's experimental eczema drug tilrekimig achieved significantly stronger skin clearance compared to placebo at multiple doses in a mid-stage clinical trial after 16 weeks. The company presented detailed Phase 2 results for the atopic dermatitis treatment.

Oct 1, 2026·1 source
00
Sep 13, 2026

Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines

Pfizer is targeting air traffic control agencies in Poland and Romania to enforce a Belgian court ruling ordering the two countries to accept €1.9 billion worth of COVID-19 vaccines they refused to take delivery of after pandemic-era demand waned.

Sep 13, 2026·1 source
00
Sep 3, 2026

AbbVie's etentamig succeeds in Phase 3 trial for multiple myeloma

AbbVie announced positive Phase 3 results for etentamig, a dual-acting T cell engager for multiple myeloma, showing survival benefits with a cleaner safety profile compared to competing BCMA-targeting therapies from Johnson & Johnson, Pfizer and Regeneron. The company is seeking to enter the crowded multiple myeloma treatment market.

Sep 3, 2026·3 sources
00
Sep 1, 2026

Kenya signs deal with Pfizer to cut cancer drug prices by more than seven times

The Kenyan government has reached an agreement with US pharmaceutical company Pfizer that will reduce the cost of cancer medications by more than sevenfold, according to President William Ruto. The deal is expected to significantly lower treatment costs for cancer patients across the country.

Sep 1, 2026·1 source
00
Aug 28, 2026

FDA approves Priovant's Lisraya for rare inflammatory disorder dermatomyositis

The FDA approved Roivant Sciences subsidiary Priovant Therapeutics' Lisraya as a once-daily pill treatment for dermatomyositis, a rare inflammatory disorder. The drug was licensed from Pfizer.

Aug 28, 2026·3 sources
00
Aug 4, 2026

Pfizer beats revenue estimates on strength of Eliquis and other drugs

Pfizer reported second-quarter revenue that exceeded analyst expectations, driven by strong sales of blood thinner Eliquis and other key medications. The company raised the low end of its full-year revenue guidance.

Aug 4, 2026·1 source
00
Jul 30, 2026

Pfizer's LITFULO Meets Primary Endpoints in Phase 3 Trials for Nonsegmental Vitiligo Treatment

Pfizer announced positive topline results from two pivotal Phase 3 studies showing LITFULO (ritlecitinib) significantly improved facial and total repigmentation compared to placebo at 52 weeks in patients with nonsegmental vitiligo. The studies represent the largest Phase 3 program to date for an oral systemic therapy in this indication.

Jul 30, 2026·1 source
00
Jun 29, 2026

Pfizer and Innovent Biologics GLP-1 Drugs Pass Preliminary Review for China Insurance Coverage

GLP-1 drugs from Pfizer and Innovent Biologics have cleared preliminary review to potentially be included in China's basic medical insurance drug catalogue, which would expand access to these treatments.

Jun 29, 2026·1 source
00
Apr 12, 2026

Two-Antibody Cocktail Developed to Combat Drug-Resistant RSV

Chinese scientists have developed a two-antibody cocktail for respiratory syncytial virus that prevented drug resistance in laboratory studies, addressing a persistent problem in RSV treatment.

Apr 12, 2026·1 source
00
Mar 26, 2026

FDA Approves Rocket Pharmaceuticals Gene Therapy for Rare Immune Disorder

The FDA approved Kresladi, Rocket Pharmaceuticals' gene therapy for a rare immune disorder, despite testing in only nine patients. The approval represents a notable decision as the agency has recently taken tougher stances on rare disease drugs.

Mar 26, 2026·3 sources
00

Top claims

  • ▪In 2024, Blackstone Inc. reached an agreement to fund trials for Moderna Inc.’s influenza vaccine, which subsequently received U.S. regulatory approval in summer 2026
  • ▪Pfizer Inc. will maintain full ownership and operational control over the clinical development program for berobenatide under its funding deal with Blackstone Inc.
  • ▪Blackstone Inc. has expanded its involvement in co-funding clinical drug development trials in recent years

Topics

Clinical trialsWeight loss drugsGLP-1 receptor agonistsDrug developmentGLP-1Pharmaceutical IndustryPrivate equityObesity treatmentCOVID-19 vaccinesPharmaceutical earningsIntellectual property & tradeMRNA vaccine technologyPharmaceutical patentsCancer and Cancer TreatmentNovo NordiskEli LillyCorporate earningsCancer treatmentCancer & OncologyFDA drug approvalOncologyTargeted cancer therapyPrecision medicineDrug Policy, Pricing & ApprovalVaccine development and innovationVaccine developmentVaccines and Immunization PolicyDrug pricing policyHealthcare PolicyTrump administration policyImmunologyInfectious Disease and OutbreaksCOVID-19PharmaClinical evaluationImmunotherapyDrug Approval and Clinical TrialsBiotechnologyClinical Trial Design & EvaluationPublic healthcareMedication Pricing & AffordabilityDrug Classes & Treatment AccessAutoimmune diseaseWeight loss medications & GLP-1 drugsLifestyle, Wellness and NutritionGLP-1 medicationsGLP-1 drugsRare Disease

Related entities

BlackstoneDelawareUnited StatesNikeEnzalutamideTalazoparibMerckImmunologyKenyaRare DiseaseAutoimmune disordersChina